Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir

Antiviral Research

Volumn 116, Issue , 2015, Pages 48-50

  Goldner, Thomas ^a   Zimmermann, Holger ^a   Lischka, Peter ^a  

^a AiCuris GmbH   (Germany)

Author keywords

AIC246; Antiviral drugs; Cytomegalovirus; HCMV; Letermovir; MK 8228

Indexed keywords

ACICLOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; LETERMOVIR; TOMEGLOVIR; ACETIC ACID DERIVATIVE; ANTIVIRUS AGENT; QUINAZOLINE DERIVATIVE; UL56 PROTEIN, CYTOMEGALOVIRUS; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EC50; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; MUTAGENESIS; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS MUTANT; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MUTATION; VIROLOGY;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

ACETATES; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MUTATION; OPEN READING FRAMES; PHENOTYPE; POLYMORPHISM, GENETIC; QUINAZOLINES; VIRAL STRUCTURAL PROTEINS;

EID: 84922718014     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.01.006     Document Type: Article

References (21)

1. E. Borst, and M. Messerle Development of a cytomegalovirus vector for somatic gene therapy Bone Marrow Transplant. 25 Suppl. 2 2000 S80 S82
2. I. Buerger, J. Reefschlaeger, W. Bender, P. Eckenberg, A. Popp, O. Weber, S. Graeper, H.D. Klenk, H. Ruebsamen-Waigmann, and S. Hallenberger A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products J. Virol. 75 2001 9077 9086
3. G. Champier, A. Couvreux, S. Hantz, A. Rametti, M.C. Mazeron, S. Bouaziz, F. Denis, and S. Alain Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole d-ribonucleoside activity Antiviral Ther. 13 2008 643 654
4. R.F. Chemaly, A.J. Ullmann, S. Stoelben, M.P. Richard, M. Bornhauser, C. Groth, H. Einsele, M. Silverman, K.M. Mullane, J. Brown, H. Nowak, K. Kolling, H.P. Stobernack, P. Lischka, H. Zimmermann, H. Rubsamen-Schaeff, R.E. Champlin, and G. Ehninger Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation N. Engl. J. Med. 370 2014 1781 1789
5. M. Chevillotte, E.J. Von, B.M. Meier, F.M. Lin, H.A. Kestler, and T. Mertens A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes Antiviral Res. 85 2010 318 327
6. T. Goldner, G. Hewlett, N. Ettischer, H. Ruebsamen-Schaeff, H. Zimmermann, and P. Lischka The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase J. Virol. 85 2011 10884 10893
7. T. Goldner, C. Hempel, H. Ruebsamen-Schaeff, H. Zimmermann, and P. Lischka Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure Antimicrob. Agents Chemother. 58 2014 610 613
8. M. Hakki, and S. Chou The biology of cytomegalovirus drug resistance Curr. Opin. Infect. Dis. 24 2011 605 611
9. G. Harter, and D. Michel Antiviral treatment of cytomegalovirus infection: an update Expert Opin. Pharmacother. 13 2012 623 627
10. D.R. Kaul, S. Stoelben, E. Cober, T. Ojo, E. Sandusky, P. Lischka, H. Zimmermann, and H. Rubsamen-Schaeff First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246 Am. J. Transplant. 11 2011 1079 1084
11. P.M. Krosky, M.R. Underwood, S.R. Turk, K.W. Feng, R.K. Jain, R.G. Ptak, A.C. Westerman, K.K. Biron, L.B. Townsend, and J.C. Drach Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56 J. Virol. 72 1998 4721 4728
12. P. Lischka, and H. Zimmermann Antiviral strategies to combat cytomegalovirus infections in transplant recipients Curr. Opin. Pharmacol. 8 2008 541 548
13. P. Lischka, G. Hewlett, T. Wunberg, J. Baumeister, D. Paulsen, T. Goldner, H. Ruebsamen-Schaeff, and H. Zimmermann In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246 Antimicrob. Agents Chemother. 54 2010 1290 1297
14. N.S. Lurain, and S. Chou Antiviral drug resistance of human cytomegalovirus Clin. Microbiol. Rev. 23 2010 689 712
15. M. Marschall, T. Stamminger, A. Urban, S. Wildum, H. Ruebsamen-Schaeff, H. Zimmermann, and P. Lischka In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses Antimicrob. Agents Chemother. 56 2012 1135 1137
16. L. Pilorge, S. Burrel, Z. Ait-Arkoub, H. Agut, and D. Boutolleau Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism Antiviral Res. 111C 2014 8 12
17. J. Reefschlaeger, W. Bender, S. Hallenberger, O. Weber, P. Eckenberg, S. Goldmann, M. Haerter, I. Buerger, J. Trappe, J.A. Herrington, D. Haebich, and H. Ruebsamen-Waigmann Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action J. Antimicrob. Chemother. 48 2001 757 767
18. A. Schreiber, G. Harter, A. Schubert, D. Bunjes, T. Mertens, and D. Michel Antiviral treatment of cytomegalovirus infection and resistant strains Expert Opin. Pharmacother. 10 2009 191 209
19. S. Stoelben, W. Arns, L. Renders, J. Hummel, A. Muhlfeld, M. Stangl, M. Fischereder, W. Gwinner, B. Suwelack, O. Witzke, M. Durr, D.W. Beelen, D. Michel, P. Lischka, H. Zimmermann, H. Rubsamen-Schaeff, and K. Budde Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study Transpl. Int. 27 2014 77 86
20. B.K. Tischer, G.A. Smith, and N. Osterrieder En passant mutagenesis: a two step markerless red recombination system Methods Mol. Biol. 634 2010 421 430
21. M.R. Underwood, R.J. Harvey, S.C. Stanat, M.L. Hemphill, T. Miller, J.C. Drach, L.B. Townsend, and K.K. Biron Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product J. Virol. 72 1998 717 725